| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 7,330 | 5,144 | 7,926 | 5,037 |
| Short-term marketable debt securities | 19 | 69 | - | 0 |
| Accounts receivable, net | 5,095 | 4,781 | 4,388 | 4,587 |
| Inventories | 1,785 | 1,825 | 1,759 | 1,869 |
| Prepaid and other current assets | 3,645 | 2,899 | 2,828 | 3,287 |
| Total current assets | 17,874 | 14,718 | 16,901 | 14,779 |
| Property, plant and equipment, net | 5,500 | 5,459 | 5,421 | 5,391 |
| Long-term marketable debt securities | 2,005 | 1,913 | - | 0 |
| Accumulated amortization-Intangible Asset Sofosbuvir | - | - | 7,923 | - |
| Accumulated amortization-Axicabtageneciloleucel DLBCL | - | - | 2,822 | - |
| Accumulated amortization-Trodelvy | - | - | 3,353 | - |
| Accumulated amortization-Hepcludex | - | - | 351 | - |
| Accumulated amortization-Other Intangible Assets | - | - | 971 | - |
| Intangible Asset Sofosbuvir | 10,720 | - | 10,720 | - |
| Axicabtageneciloleucel DLBCL | 7,110 | - | 7,110 | - |
| Trodelvy | 11,730 | - | 11,730 | - |
| Hepcludex | 845 | - | 845 | - |
| Other Intangible Assets | 1,479 | - | 1,479 | - |
| Net carrying amount | - | 15,866 | - | 17,656 |
| Finite Lived Intangible Assets Gross | 31,884 | - | 31,884 | - |
| Indefinite Lived Intangible Assets Excluding Goodwill | 2,700 | 2,700 | 2,890 | - |
| Gross carrying amount | 34,584 | - | 34,774 | - |
| Accumulated amortization | 16,614 | - | - | - |
| Intangible Asset Sofosbuvir | 0 | - | 0 | - |
| Axicabtageneciloleucel DLBCL | 0 | - | 0 | - |
| Trodelvy | 0 | - | 0 | - |
| Hepcludex | 0 | - | 0 | - |
| Other Intangible Assets | 0 | - | 1 | - |
| Finite Lived Intangible Assets Foreign Currency Translation Gain Loss Cumulative Gain Loss | 0 | - | 1 | - |
| Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss Cumulative Gain Loss | 0 | 0 | 0 | - |
| Net carrying amount | - | 2,700 | - | 2,890 |
| Foreign currency translation adjustment | 0 | - | 1 | - |
| Intangible assets, net | 17,970 | 18,566 | 19,355 | 20,546 |
| Goodwill | 8,314 | 8,314 | 8,314 | 8,314 |
| Deferred tax assets | 1,998 | 2,721 | 2,572 | - |
| Other long-term assets | 4,873 | 4,031 | 3,871 | 5,494 |
| Total assets | 58,533 | 55,721 | 56,434 | 54,525 |
| Accounts payable | 808 | 582 | 737 | 903 |
| Accrued rebates | 4,931 | 4,215 | 4,185 | 4,113 |
| Current portion of long-term debt, net | 2,806 | 2,806 | 2,806 | 1,812 |
| Other current liabilities | 3,752 | 3,586 | 4,615 | 4,896 |
| Total current liabilities | 12,298 | 11,189 | 12,344 | 11,725 |
| Long-term debt, net | 22,135 | 22,140 | 22,146 | 21,437 |
| Long-term income taxes payable | 866 | 859 | 819 | 782 |
| Deferred tax liabilities | 597 | 652 | 709 | 794 |
| Other long-term liabilities | 1,182 | 1,290 | 1,337 | 1,396 |
| Common stock, par value 0.001 per share 5,600 shares authorized 1,242 and 1,246 shares issued and outstanding, respectively | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 8,678 | 8,367 | 8,138 | 7,327 |
| Accumulated other comprehensive income | 36 | -18 | 92 | 73 |
| Retained earnings | 12,825 | 11,325 | 10,931 | 11,073 |
| Total gilead stockholders equity | 21,540 | 19,674 | 19,162 | 18,475 |
| Noncontrolling interest | -84 | -84 | -84 | -84 |
| Total stockholders equity | 21,456 | 19,590 | 19,078 | 18,390 |
| Total liabilities and stockholders equity | 58,533 | 55,721 | 56,434 | 54,525 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)